ArticleScientific reports2025
Survival outcomes and prognostic factors of early-onset and late-onset metastatic esophageal cancer: a population-based study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of a prognostic prediction model incorporatingJournal of gastrointestinal oncology · 2026Article
- Identification of Prognostic Factors in Esophageal Cancer Using Machine Learning: A Retrospective Study Based on the SEER Database.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In recent years, the incidence of malignancies among young people, including early-onset esophageal cancer (EOEC), has been increasing globally. This study aims to compare the survival outcomes of metastatic EOEC and late-onset esophageal cancer (LOEC) and to identify prognostic factors. Patient data were collected from the Surveillance, Epidemiology, and End Results database. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using univariate and multivariate Cox regression models. Propensity score matching (PSM) was applied to balance baseline differences. The Kaplan-Meier method and log-rank test were used to compare overall survival (OS). A total of 11,738 cases of metastatic esophageal cancer were included from 2010 to 2020, with 996 EOEC patients and 10,742 LOEC patients. The mean OS for EOEC patients was 14.30 months (95% CI 12.53-16.06 months), compared to 10.89 months (95% CI 10.45-11.33 months) for LOEC patients. Multivariate Cox regression analysis revealed that marital status, histological type, tumor grade, bone metastasis, liver metastasis, surgery, and chemotherapy were independent prognostic factors for EOEC patients (p < 0.05). After adjusting for variables other than age using PSM, the results still indicated better OS for EOEC patients (p = 0.031). Further subgroup analysis showed that chemotherapy primarily influenced survival outcomes in both groups (p = 0.012). Metastatic EOEC showed better OS outcomes compared to LOEC, and EOEC patients benefited more from chemotherapy than LOEC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.